Isoflavones found in soy products can help reduce the risk of developing early prostate cancer in men who have consumed soy their entire lives but might also increase the risk of advanced prostate cancer.
U.S. researchers identified a biomarker called galectin-3 that appears to split during the progression of prostate cancer. They also found that lowering the levels of the biomarker blocked the development of metastatic prostate cancer. The findings indicate that the cleaved form of galectin-3 might be used as a diagnostic marker of the disease and potential target for drugs.
The FDA approved Merck's diabetes treatment Janumet, a combination of its diabetes drug Januvia, which was approved just last year, and the older drug metformin. Janumet is the first pill to treat Type 2 diabetes by targeting all causes of the disease. Analysts expect Janumet and Januvia to bring in more than $2 billion in annual sales for Merck.
Abbott Laboratories and Japan's Astellas Pharma filed suit to prevent the FDA from allowing Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd. and Novartis AG's Sandoz unit to market a generic version of the antibiotic Omnicef. The treatment for ear, sinus, throat and skin infections had $637 million in sales last year for Abbott, which claims the Omnicef patent is good until 2011.
A study of nearly 70,000 men between 1982 and 1992 found that losing weight can reduce the risk of aggressive prostate cancer. Men in the study who lost more than 11 pounds had a lower risk for the disease than those whose weight remained the same over a decade.